The arrival of generic semaglutide in Canada marks a major turning point for one of the world’s most closely watched classes of medicine. Between April 28 and June 29, 2026, Health Canada authorized three generic semaglutide products—two referencing Ozempic for type 2 diabetes and one referencing Wegovy for chronic weight management.
Canada became the first G7 country to approve a generic semaglutide when it cleared Dr. Reddy’s version in April. Apotex followed three days later with a Canadian-based alternative, before receiving authorization for Sevmia, the country’s first generic semaglutide specifically approved for weight management. The decisions could eventually lower costs and broaden treatment options, although regulatory approval does not guarantee immediate availability, insurance coverage or dramatic price reductions at every pharmacy.
Dr. Reddy’s Semaglutide Opens the G7 Market
Health Canada authorized Dr. Reddy’s Semaglutide Injection on April 28, making it the first generic semaglutide approved in Canada and across the G7. The product is a generic equivalent of Ozempic and is approved as a once-weekly treatment for adults with type 2 diabetes who require additional help controlling their blood sugar. Its authorization covers pre-filled pen presentations containing 2 milligrams and 4 milligrams of semaglutide, corresponding to dosing options already familiar to many Ozempic patients. Health Canada completed its review within its 180-day target, although periods when the manufacturer was supplying additional information were not counted toward that target. At the time of approval, eight other generic semaglutide submissions were still being examined, showing how quickly manufacturers were preparing to compete once Canadian patent and data-protection barriers permitted entry.
Calling the medicine “generic” does not mean Health Canada treated it as a simple copy. Semaglutide is a complex synthetic peptide, requiring manufacturers to demonstrate pharmaceutical equivalence, consistent manufacturing and comparable performance to the Canadian reference product. Dr. Reddy’s product was listed as marketed in early May, but approval and dependable supply have not moved in a perfectly straight line. In July, the company disclosed that an impurity had been detected while production of its active ingredient was being scaled up. It paused new production, with additional shipments expected to be disrupted until at least late October. The company said doses already distributed in Canada were not affected. For patients, that distinction matters: a medicine can be authorized and technically on the market while still being difficult for some pharmacies to obtain consistently.
The supply interruption also demonstrates why three approvals may prove more valuable than a single first-to-market product. A person managing diabetes generally needs predictable refills rather than occasional access to a lower-priced pen. Multiple suppliers can provide alternatives when one manufacturer encounters production constraints, although each product remains subject to its own availability, dispensing rules and provincial coverage decisions. Health Canada says many generic medicines in Canada cost between 45 and 90 per cent less than their brand-name equivalents. That range should not be interpreted as a guaranteed discount for semaglutide, however. Final patient costs can depend on manufacturer pricing, pharmacy fees, public formularies, private insurance and whether a plan requires substitution with a generic product.
Apo-Semaglutide Adds Canadian Competition
Apotex received authorization for Apo-Semaglutide Injection on May 1, only three days after the first approval. That made the Toronto-based company the first Canadian-based global manufacturer to secure approval for a generic equivalent of Ozempic. The product is offered in two multi-dose pre-filled pen formats: one containing 2 milligrams of semaglutide that delivers either 0.25-milligram or 0.5-milligram doses, and another containing 4 milligrams that delivers 1-milligram doses. Like the Dr. Reddy’s version, it is approved for once-weekly use by adults with type 2 diabetes, alongside diet and exercise and in combinations described in its product monograph. Health Canada’s database listed Apo-Semaglutide as marketed as of May 14, giving pharmacies another authorized source shortly after the Canadian generic market opened.
The product was developed through a partnership between Apotex and India-based Orbicular Pharmaceutical Technologies, illustrating how even a Canadian-branded generic can rely on international scientific and manufacturing collaboration. When this second product was approved, seven additional semaglutide submissions remained under review. That pipeline suggested Canada’s market could become considerably more crowded, placing pressure on both generic manufacturers and Novo Nordisk, the producer of Ozempic and Wegovy. Competition may encourage lower prices, but it can also reward manufacturers capable of keeping enough pens in stock. Semaglutide production involves more complicated chemistry, quality controls and injection-device manufacturing than many conventional generic tablets, making reliable supply an important part of the competition.
For patients, the most important question is whether a generic will work like the medication it replaces. Health Canada requires a generic to contain the same medicinal ingredient in the same amount and a similar dosage form as its reference product. Manufacturers must also show that differences in non-medicinal ingredients, packaging or production do not meaningfully alter safety, effectiveness or quality. Generic products may carry a different name and use a pen that looks or operates somewhat differently, but they are not approved as weaker versions of the original medicine. Provincial legislation and individual drug-plan policies can allow or require pharmacists to dispense a generic once one becomes available. Patients who notice a change in the product, pen or instructions are encouraged by Health Canada to speak with their pharmacist rather than assume that every device is handled identically.
The approval could be particularly meaningful for people whose insurance previously limited semaglutide coverage or who paid much of the cost themselves. A lower list price can reduce direct expenses and may make it easier for public and private plans to cover larger patient populations. Still, savings are unlikely to appear evenly across Canada. A drug may be authorized federally before being listed by a provincial plan, and private insurers can establish their own eligibility requirements. The opening of the generic market is therefore better understood as the beginning of a pricing and access shift—not an overnight guarantee that every Canadian prescription will immediately become inexpensive.
Sevmia Extends Generics Into Weight Management
Health Canada authorized Sevmia on June 29, with Apotex announcing the decision the next day. It was the third generic semaglutide product approved nationally and the first referencing Wegovy rather than Ozempic. That difference is important because the authorized uses are not interchangeable. Sevmia is indicated as part of chronic weight management for adults with a body mass index of at least 30, or at least 27 when accompanied by a weight-related condition such as hypertension, type 2 diabetes, abnormal cholesterol or obstructive sleep apnea. It is also authorized for eligible adolescents aged 12 to under 18 who meet age- and sex-based obesity criteria, weigh more than 60 kilograms and have not responded adequately to nutrition and physical-activity measures alone. The product also carries an indication for reducing the risk of non-fatal heart attack in adults with established cardiovascular disease and a BMI of at least 27.
The initially authorized Sevmia presentation is a multi-use pen delivering 1-milligram doses. That creates an important practical limitation. The product monograph describes a gradual escalation beginning at 0.25 milligrams weekly and moving through 0.5, 1, 1.7 and ultimately 2.4 milligrams, generally increasing every four weeks to reduce gastrointestinal symptoms. Because Sevmia’s approved pen delivers only the 1-milligram dose, its monograph states that alternative products are required for other stages of the schedule. In other words, the approval establishes a generic option within weight-management treatment, but the first presentation may not independently cover every dose needed from initiation through maintenance. Prescribers, pharmacists and insurers will need to account for that when constructing a complete treatment plan.
The clinical interest surrounding semaglutide is supported by substantial research on the reference medicine. In the STEP 1 randomized trial, adults with overweight or obesity who received weekly semaglutide alongside lifestyle intervention lost an average of 14.9 per cent of their starting weight over 68 weeks, compared with 2.4 per cent among those receiving placebo and lifestyle intervention. Those results should not be interpreted as a promise that every patient will experience the same outcome. Individual responses vary, and nausea, vomiting, diarrhea, constipation and other gastrointestinal effects are common reasons for slower dose escalation or discontinuation. The authorized monograph also includes significant contraindications and precautions, including restrictions involving pregnancy, breastfeeding, certain thyroid-cancer histories and the use of other semaglutide or GLP-1 medicines.
For a family seeking treatment for an adolescent with severe obesity, or an adult facing both obesity and cardiovascular disease, a less expensive authorized option could make long-term therapy more attainable. However, semaglutide remains a prescription medicine intended for patients who meet specific clinical criteria—not a general-purpose cosmetic weight-loss product. The three Canadian approvals represent a landmark in pharmaceutical competition, but their ultimate impact will depend on pricing, consistent production, additional dose formats and whether public and private drug plans translate authorization into affordable access.
